Abbott has announced that a new cardiac ablation catheter it has developed for the treatment of atrial fibrillation has received European CE Mark approval.
The TactiCath Contact Force Ablation Catheter, Sensor Enabled device has been integrated with Abbott's EnSite Precision cardiac mapping system, allowing dual impedance and magnetic technologies to be utilised to more precisely model the heart.
“Abbott has received European CE Mark approval for its new TactiCath Contact Force Ablation Catheter, Sensor Enabled product for the treatment of atrial fibrillation.“
Physicians can determine where to apply optimal contact force when creating a lesion during a cardiac ablation to correct a heart rhythm abnormality, while the Sensor Enabled technology allows detailed heart models to be created.
It represents a significant advance on the existing TactiCath Contact Force Catheter product family, which represents the most-studied contact force ablation catheter platform on the market, and is associated with strong clinical success rates.
Dr Srijoy Mahapatra, medical director of Abbott's electrophysiology business, said the device is designed to "provide the most innovative solution for treating atrial fibrillation and lead the way in clinical outcomes for patients with cardiac arrhythmias - even during long and complex ablation procedures".
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices